Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026

Bulletin Express04-14

Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).

According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.

Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.

The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.

Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188331019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188331019","market":"us","top_or_hot":-1,"title":"Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).</p>\n<p>According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.</p>\n<p>Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.</p>\n<p>The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.</p>\n<p>Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-14 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).</p>\n<p>According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.</p>\n<p>Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.</p>\n<p>The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.</p>\n<p>Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1188331019","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188331019","pubTimestamp":1776168205,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI®...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞：传奇生物斥资5.97亿美元收购CARVYKTI®2026年第一季度净销售额","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).\nAccording to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.\nLegend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.\nThe announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.\nGenscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188331019","isCrawlerRequest":true}